High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort

• Halfdan Sorbye ,

  * E-mail: halfdan.sorbye@helse-bergen.no

  Affiliation Department of Oncology, Haukeland University Hospital, Bergen, Norway

  ⨯
• Anca Dragomir,

  Affiliations Department of Pathology, Uppsala University Hospital, Uppsala, Sweden, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

  ⨯
• Magnus Sundström,

  Affiliation Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

  ⨯
• Per Pfeiffer,

  Affiliation Department of Oncology, Odense University Hospital, Odense, Denmark

  ⨯
• Ulf Thunberg,

  Affiliation Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

  ⨯
• Monica Bergfors,

  Affiliation Department of Pathology, Uppsala University Hospital, Uppsala, Sweden

  ⨯
• Kristine Aasebø,

  Affiliation Department of Oncology, Haukeland University Hospital, Bergen, Norway

  ⨯
• Geir Egil Eide,

  Affiliation Department of Global Public Health and Primary Care, Lifestyle Epidemiology Group, University of Bergen, Bergen, Norway

  ⨯
• Fredrik Ponten,

  Affiliation Science for Life Laboratory, Uppsala University, Uppsala, Sweden

  ⨯
• Camilla Qvortrup,

  Affiliation Department of Oncology, Odense University Hospital, Odense, Denmark

  ⨯
• Bengt Glimelius

  Affiliation Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

  ⨯